摘要
目的 探讨三维适形放疗（3DCRT）、序贯化疗的不同模式治疗局部晚期非小细胞肺癌（LANSCLC）的临床疗效。方法2001年7月-2006年12月，83例符合人组标准的LANSCLC患者纳入本研究，根据放疗的参与时机分为三组，1组：诱导化疗1—2周期＋放疗组；2组：诱导化疗3—4周期＋放疗组；3组：诱导化疗5—6周期＋放疗组。放射治疗均采用3DCRT技术，化疗采用以顺铂为主的联合化疗方案，对比观察三组患者的近期疗效，1、2年生存率，中位生存期和毒副反应。结果：三组患者的总有效率分别为89．3％、78．1％和68．5％（P〉0．05）。三组患者的1、2年生存率分别为75．00％、67．86％、51．16％和49．01％、44．44％、31．97％，中位生存期分别为21个月、18个月和16个月（P〈0．05）。三组的毒副反应发生率无显著性差异。全组患者的1、2年生存率为64．87％和41．56％，中位生存期20个月。ⅢA和ⅢB期患者的中位生存期分别为21个月和16个月（P〈0．05）。结论3DCRT联合应用序贯化疗是安全和有效的，两者的联合应用能够提高LANSCLC的临床疗效。在序贯放化疗模式中，各组研究结果显示放疗的尽早参与能够提高LANSCLC患者的临床疗效，诱导化疗次数以1—2周期为宜，增加诱导化疗的次数没有带来生存益处。
Objective To evaluate the outcome of locally advanced non - small cell lung cancer treated with radiotherapy and chemotherapy. Methods From July 2001 to December 2006,83 patients with locally advanced non - small cell lung cancer were enrolled. Three groups were divided based on time and sequence of radiotherapy and chemotherapy. All patients used three dimensional conformal radiation therapy and eisplatin based chemotherapy. The shortterm response and 1 -year,2 -year survival rates, median survival time and toxicity in three groups were compared. Results The overall response in three groups were 89.3% ,78.1% and 68.5 % （P 〉 0.05 ） respectively. The median survival time were 21 months, 18 months and 16 months, respectively, The 1 - , 2 - year survival rate were 75 % ,67.86% ,51.16% and 49.01% ,44.44% , 31.97 % （ P 〈 0.05 ） respectively for three groups. And the differences of toxicity rates for three groups were not statistically significant. Conclusion Induction chemotherapy followed by three dimensional conformal radiation therapy was efficacy and safety. The sequential chemoradiotherapy improved the overall survival of locally advanced non - small cell lung cancer. The output indicated early irradiation with ehemoradiotherapy is superior to late irradiation. Induction chemotherapy is optimization for one or two cycles.
出处
《实用肿瘤学杂志》
CAS
2010年第1期48-52,共5页
Practical Oncology Journal
关键词
非小细胞肺癌
适形放疗
诱导化疗
Non -small cell lung eancer
Conformal radiotherapy
Induction chemotherapy
